327 related articles for article (PubMed ID: 32703223)
1. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
3. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
5. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
7. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.
Calhoun EA; Welshman EE; Chang CH; Lurain JR; Fishman DA; Hunt TL; Cella D
Int J Gynecol Cancer; 2003; 13(6):741-8. PubMed ID: 14675309
[TBL] [Abstract][Full Text] [Related]
8. Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20).
Abu Sharour L
Appl Neuropsychol Adult; 2021; 28(5):614-618. PubMed ID: 31612735
[TBL] [Abstract][Full Text] [Related]
9. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
10. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
[TBL] [Abstract][Full Text] [Related]
11. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
[TBL] [Abstract][Full Text] [Related]
12. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.
Huang HQ; Brady MF; Cella D; Fleming G
Int J Gynecol Cancer; 2007; 17(2):387-93. PubMed ID: 17362317
[TBL] [Abstract][Full Text] [Related]
13. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
Zirpoli GR; McCann SE; Sucheston-Campbell LE; Hershman DL; Ciupak G; Davis W; Unger JM; Moore HCF; Stewart JA; Isaacs C; Hobday TJ; Salim M; Hortobagyi GN; Gralow JR; Budd GT; Albain KS; Ambrosone CB
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546345
[TBL] [Abstract][Full Text] [Related]
14. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
15. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review.
Haryani H; Fetzer SJ; Wu CL; Hsu YY
Oncol Nurs Forum; 2017 May; 44(3):E111-E123. PubMed ID: 28635977
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
Kieffer JM; Postma TJ; van de Poll-Franse L; Mols F; Heimans JJ; Cavaletti G; Aaronson NK;
Qual Life Res; 2017 Nov; 26(11):2999-3010. PubMed ID: 28634676
[TBL] [Abstract][Full Text] [Related]
18. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.
Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C
Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913
[TBL] [Abstract][Full Text] [Related]
19. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
20. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
Weber B; Largillier R; Ray-Coquard I; Yazbek G; Meunier J; Alexandre J; Dauba J; Spaeth D; Delva R; Joly F; Pujade-Lauraine E; Copel L;
Support Care Cancer; 2013 Jul; 21(7):1947-54. PubMed ID: 23420555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
